Suchergebnisse - "Calmy, A"

PubPharm (363)

71

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

enthalten in: BMC infectious diseases | 2019

von Surial, B. | Cavassini, M. | Calmy, A. | +61

72

Screening HIV-positive men who have sex with men for hepatitis C re-infection risk : is a single question on condom-use enough? A sensitivity analysis

enthalten in: BMC infectious diseases | 2019

von Künzler-Heule, P. | Engberg, S. | Battegay, M. | +67

73

Population pharmacokinetics of dolutegravir : influence of drug-drug interactions in a real-life setting

enthalten in: The Journal of antimicrobial chemotherapy | 2019

von Barcelo, C. | Aouri, M. | Courlet, P. | +60

74

Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1

enthalten in: The New England journal of medicine | 2019

von NAMSAL ANRS 12313 Study Group | Kouanfack, C. | Mpoudi-Etame, M. | +75

CommentIn: N Engl J Med. 2019 Aug 29;381(9):873-874. - PMID 31339675

75

Emtricitabine and lamivudine concentrations in saliva : a simple suitable test for treatment adherence

enthalten in: The Journal of antimicrobial chemotherapy | 2019

von Courlet, P. | Decosterd, L. | Brown, J. | +59

76

Reply to "Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on : Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis" by S. Noe, H. Jaeger, E. Wolf

enthalten in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA | 2019

von Biver, E. | Calmy, A. | Meier, C.

CommentOn: Osteoporos Int. 2019 May;30(5):1125-1135. - PMID 30603840

77

Why do sub-Saharan Africans present late for HIV care in Switzerland?

enthalten in: HIV medicine | 2019

von Hachfeld, A. | Darling, K. | Calmy, A. | +61

78

Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf

enthalten in: Osteoporosis international | 2019

von Biver, E. | Calmy, A. | Meier, C.

79

Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf

enthalten in: Osteoporosis international | 2019

von Biver, E. | Calmy, A. | Meier, C.

80

Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf

enthalten in: Osteoporosis international | 2019

von Biver, E. | Calmy, A. | Meier, C.